
The estimated cost for US nuclear weapons nears $1 trillion in new report
The nonpartisan Congressional Budget Office estimates nuclear forces will cost $946 billion from 2025 through 2034, about $95 billion every year. In 2023, the 10-year estimate was $756 billion for 2023-2032. Some of those increases are coming from the cost for modernizing production facilities for nuclear weapons and delivery systems. Projected costs for command, control, communications and early-warning systems have also seen a substantial increase.
The co-founder of an anti-nuclear nonprofit called the increase staggering. A higher bar for laboratory safety standards contributes to the high price for producing new nuclear warheads, according to a professor on nuclear engineering.
Many of the country's nuclear forces, including submarines that launch ballistic missiles, land-based intercontinental ballistic missiles, long-range bomber aircraft and shorter-range tactical aircraft carrying bombs and nuclear warheads, will need to be refurbished or replaced over the next 20 years, according to the report.
"Over the coming years, lawmakers will need to decide what nuclear forces the United States should field in the future and therefore the extent to which the nation will continue to modernize, and perhaps expand, those forces," the report states.
Some of the cost increase, at least $65 billion, does not reflect actual rising costs. Instead, it's simply because the new estimate focuses on a slightly later time period when nuclear arsenal modernization will be further along. Later development and production phases tend to be more expensive, according to the report.
Los Alamos National Laboratory in New Mexico, overseen by the National Nuclear Security Administration, is one of two sites that will produce new plutonium pits to replace old warheads. Last year, the lab made its first new production unit plutonium pit. Spherical plutonium pits cause nuclear fission when compressed and are at the core of every nuclear explosive.
The majority of the projected cost increases are associated with Department of Defense programs. But the "laboratories, plants, and sites across the nation are an integral part of our nuclear security program," an NNSA spokesperson said in a statement. President Donald Trump and Energy Secretary Chris Wright are committed to "modernizing our nuclear deterrent," the spokesperson said.
"NNSA is currently executing seven different warhead modernization programs which require the national security laboratories' expertise in weapons programs, design and engineering, and production," the spokesperson said.
The first-ever plutonium pits were made during the Manhattan Project at Los Alamos, but many subsequent pits were produced in Colorado until the 1980s. The way pits are manufactured now has changed significantly from how it was done decades ago, said Carl Willis, a professor in the University of New Mexico's Department of Nuclear Engineering.
What is considered acceptable in terms of safety for human health and the environment has changed since the country previously made plutonium pits, contributing to a higher production cost, Willis said.
"We're building these new facilities from scratch, and the understanding of industrial hygiene, and particularly the hygiene of handling plutonium, has changed, and our ability to detect plutonium in the environment has gotten a lot better," Willis said.
Greg Mello, with the anti-nuclear nonprofit Los Alamos Study Group, called for Congress to kill the Sentinel intercontinental ballistic missile program based on the CBO report. The Sentinel program is replacing Minuteman III missiles with Sentinel missiles, as well as upgrading missile silos and launch control centers. Los Alamos is building plutonium pits to be used in Sentinel missiles.
The CBO report does not include all the cost growth that the Sentinel program is likely to experience, because the Department of Defense is restructuring the program after its cost increases triggered a review.
"As CBO notes, there will be increased competition for defense dollars as nuclear weapons programs grow. The huge expenses tallied in this report were not anticipated at the outset of the nuclear modernization program," Mello said in a statement. "Since 2015, and with every report, estimated nuclear weapons costs have increased beyond prior predictions, from $348 billion in 2015 to $946 billion today. The opportunity costs are staggering."
The cost for nuclear weapons could be even higher in the next CBO estimate, Willis said, because the latest report does not consider Trump administration priorities.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Pfizer battles another Paxlovid lawsuit from Enanta
If you don't succeed at first, try again – in separate regions. That's the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent infringement relating to Covid-19 treatment pill Paxlovid (nirmatrelvir/ritonavir). In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma company infringed on a patent describing protease inhibitors invented by its scientists. Enanta has now followed that up with another filing in Europe, making the same accusation. Since being emergency authorised in 2021, anti-viral Paxlovid has generated Pfizer more than $26bn in global revenue. This includes a staggering $18.9bn in 2022 when Covid-19 cases were still prevalent. Despite waning demand for Covid-19 treatments, the pill still brought in $1.2bn in 2024, buoyed by government orders. However, Enanta – known for co-developing hepatitis C virus treatment glecaprevir/pibrentasvir with AbbVie – believes Pfizer designed Paxlovid via unlawful means. The US biotech stated it is 'seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '265 Patent) in the manufacture, use and sale of Pfizer's Covid-19 antiviral, Paxlovid'. In an emailed statement to Pharmaceutical Technology, a Pfizer spokesperson said: 'We are confident in our intellectual property (IP) surrounding Paxlovid and will respond in due course in court.' The lawsuit, filed in the European Union's (EU) Unified Patent Court (UPC), targets Pfizer's commercial activity in the 18 countries of the EU. The company confirmed the '265 patent in question is the European counterpart of US patent number 11,358,953 (the '953 Patent) that is the centre of the US lawsuit. Although it is technically ongoing, Enanta's US lawsuit hit a major roadblock. In December 2024, a federal judge in Massachusetts sided with Pfizer, granting that the '953 patent is invalid. Enanta confirmed at the time it would appeal the decision, adding it 'believes strongly in the merits of our case'. Pfizer reported strong Q2 2025 results this month, bucking a tepid earnings window that gripped the wider pharma industry. Sales for the Paxlovid grew 71% while the Covid-19 vaccine Comirnaty revenue surged 95%. However, the legal challenge posed by Enanta marks the second issue Pfizer has had to firefight this week. The big pharma company reported a Phase III trial failure for a sickle cell disease candidate purchased as part of a $5.4bn takeover of Global Blood Therapeutics in 2022. "Pfizer battles another Paxlovid lawsuit from Enanta" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
11 minutes ago
- Yahoo
Nasdaq slides again as AI jitters rattle tech investors
NEW YORK (Reuters) -Tech stocks are leading declines on Wall Street, with worries about AI spurring debates about its future. The Nasdaq Composite is down around 2.4% over the last two days, the worst two-day fall since April. The semiconductor index was down 1.5%, while the information technology sector was the second biggest decliner in the S&P 500, dropping 1.1% on Wednesday. Market participants attributed the selloff to a range of factors including a technical pullback after driving much of the stock market's recovery in the weeks after April 2nd "Liberation Day." Analysts also cited deepening concerns of government interference with companies, as the Trump administration looked into taking equity stakes in chip companies such as Intel in exchange for grants under the CHIPS Act. COMMENTS: ART HOGAN, MARKET STRATEGIST, B. RILEY WEALTH MANAGEMENT, BOSTON: "Technology in general is up 40% from its April lows, and the group clearly got ahead of itself. Also, if there's anything to the market consensus that we'll see a Fed rate cut, then there will be room for other things to work as well – and there are 493 other stocks in the S&P 500 that are lagging the Mag 7 right now. So I think there's a bit of a rotation." "I don't know how long it will last, but if it does keep going, well, August and September (are) the weak period seasonally in which it could do so. Also, there are some people who are beginning to question the pace at which we need to be chasing AI capital spending. If you put all this together: when technology stocks take a breather, this is what it looks like. Nvidia and other blue chips in the group are seeing relatively steady drawdowns, but things on the speculative edge are clearly seeing more selling pressure. Palantir has gone from trading at 200 times sales to 150 times its sales, for instance." MICHAEL ASHLEY SCHULMAN, CHIEF INVESTMENT OFFICER, RUNNING POINT, EL SEGUNDO, CALIFORNIA: "Tuesday' s U.S. technology stock swoon and its continuation today looks like multiple compression meeting a little margin math, but the timing makes it hard to ignore the new elephant in the server room. Names that had been sprinting on AI dreams pulled back hard, with Nvidia, AMD, and Palantir Technologies among the drags." "DeepSeek's update landed on Tuesday represents a serious cocktail of capability and availability and traders well remember the original harsh tech-market pullback DeepSeek caused when it was first broadly recognized in January of this year." BRIAN JACOBSEN, CHIEF ECONOMIST, ANNEX WEALTH MANAGEMENT, BROOKFIELD, WISCONSIN: "When you go from rally to rout, it shows how vulnerable the names were to even a scent of bad news. It could have been (Sam)Altman's valuation warning and then Meta restructuring its AI division threw fuel on the fire." PHIL BLANCATO, CHIEF EXECUTIVE OFFICER, LADENBURG THALMANN ASSET MANAGEMENT, NEW YORK: "It's much more about profit-taking and temporary rebalancing here. If you get a Federal Reserve cut or a mention of it on Friday, this will reverse pretty quickly, but this is a lot to do with names pushed up to really lofty levels and profit taking across the board." SETH HICKLE, PORTFOLIO MANAGER, MINDSET WEALTH MANAGEMENT, INDIANAPOLIS: "I think we are starting to see a little bit of rotation. It's always healthy to see a little bit of a pullback to that way, the markets can kind of get re-oriented." "To me, tech was overbought. Maybe it was justified, but it could have been kind of a buy on the rumor, sell it on the news type of thing where we had tech runup into earnings. We had really good earnings, and now it's kind of natural for the market just to sell some of that good news." "I wouldn't be surprised if we see a little bit of rotation into some smaller cap or into healthcare names, or consumer staples. And to me, that's kind of a healthy rotation. But honestly, I don't believe it will be a longer-term trend. It'll probably be a shorter-term trend. I think we'll see money flow back into tech in the next couple months." STEVE SOSNICK, CHIEF STRATEGIST, INTERACTIVE BROKERS, CONNECTICUT "The tech-led selloff that we saw yesterday resumed this morning. That said, dip buyers stepped in around 11am EDT and we've now recovered about half our losses. It's somewhat inevitable to expect them to arrive promptly, though it did take a bit longer than usual." "I believe that some of the early declines are related to profit-taking and risk squaring ahead of (Fed Chair Jerome)Powell's speech on Friday. That is merely rotation and relatively benign, though it gets magnified because of megacap tech stocks' heavy weighting in key indices. But some of the ferocity of the early drop was related to the President's calls for Lisa Cook's resignation." "Note that futures broke through their pre-market lows shortly after he posted on Truth Social. Markets were not perturbed that there are inquiries into the propriety of her personal mortgage applications. She gets a presumption of innocence until proven guilty, like any other person. But when the President weighed in even before the process began, then it raised the specter of politicization. That put markets on the wrong foot early, and negative momentum ruled again – at least for a couple of hours." ADAM SARHAN, CHIEF EXECUTIVE, 50 PARK INVESTMENTS, NEW YORK: "To see a little pullback here after a big move up is perfectly normal and healthy. If the selling gets worse then you'll see a rotation out of tech and into undervalued areas of the market like biotech stocks or healthcare stocks or small cap stocks because those areas have not participated this year." Sign in to access your portfolio
Yahoo
11 minutes ago
- Yahoo
TX RX Systems Launches New 'Deepwave' Antenna Line to Fill Industry Gap
TX RX Systems Deepwave Antennas BUFFALO, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- TX RX Systems, a leader in RF conditioning and communications technology for nearly five decades, has announced the launch of its new Deepwave antenna series. This is a comprehensive product line designed to serve as the next-generation solution for organizations seeking high-performance VHF and UHF omnidirectional antennas similar to those found in now-unavailable legacy lines. Engineered and manufactured on-site in the United States, Deepwave antennas deliver industry-proven performance at a significantly lower cost than comparable offerings currently available in the market. Designed for both mission-critical and commercial applications, the line is suitable for integrators, public safety agencies, utilities, transportation providers, manufacturing facilities, government entities, and any organization requiring durable, broadband RF coverage. The new Deepwave series features wideband coverage across VHF and UHF ranges, allowing flexible deployment across multiple systems and jurisdictions. Models are available with nominal gains ranging from 3 dBd to 9 dBd, providing consistent coverage and minimal distortion throughout the entire operating band. Low VSWR, typically 1.5:1 or less across the specified frequency range, ensures efficient power transfer and reduced reflected power. Each antenna is designed to handle high transmit power levels, making them ideal for both high-site and dense urban installations. Durability is a core design priority for the Deepwave line. Heavy-duty fiberglass radomes and stainless steel hardware protect against extreme weather conditions including high winds, ice loading, and salt fog exposure. All models are engineered to meet or exceed ANSI/TIA-222 standards for structural integrity, ensuring reliable operation even in the harshest environments. 'With the discontinuation of several long-standing antenna product lines in the market, organizations are actively seeking drop-in replacements that match or exceed the performance of their existing infrastructure,' said Jay Slomba, Director of Business Operations at TX RX Systems. 'Deepwave antennas are engineered to deliver uncompromising quality at a price point well below what customers are used to paying.' The Deepwave series is available now through the TX RX Systems website. Additional models will be released in the coming months to expand the range and cover even more application requirements. For more information or to request a quote, visit or contact a TX RX Systems Customer & Technical Support Specialist at sales@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data